Pleural Fluid Neutrophil Extracellular Traps Exacerbate Disease Severity and Risk of One-year Mortality in Pleural Infection (TORPIDS-3)

NCT07194915 | Active Not Recruiting

• 1 other identifier: TORPIDS-3
• Study Type: observational
• Target: 326
• Locations: 1 country
• Sites: 1

Brief Summary

Pleural infection is a severe and complicated disease which is associated with significant morbidity and mortality. People with pleural infection show diverse levels of neutrophil degranulation activity. The investigators examined the biological role of pleural fluid neutrophil extracellular traps in patients with pleural infection. TORPIDS-3 is an observational, International multicohort study.

Conditions

Pleural Infection

Keywords

pleural infection; neutrophils; neutrophil extracellular traps; NETs; inflammation

Outcome Measures

Primary Outcomes (2)

• Disease severity

  Association between pleural fluid NETs with disease severity

  Baseline

• One-year mortality

  Association between pleural fluid NETs and risk of one-year mortality

  Baseline

Secondary Outcomes (3)

• Bacterial profiles

  Baseline

• Sonographic septations

  Baseline

• Need for Intrapleural Enzyme Therapy (IET)

  Baseline

Study Arms (5)

PILOT

Pleural fluid specimens collected for the PILOT study

Oxford Pleural Biobank

Pleural fluid specimens collected in Oxford

Oxford-Osler

Pleural fluid specimens collected in Oxford

Patras Pleural Biobank

Pleural fluid specimens collected in Patras, Greece

Ancona Pleural Biobank

Pleural fluid specimens collected in Ancona, Italy

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Patients with confirmed pleural infection

You may qualify if:

• Patients were included if they had a clinical presentation consistent with pleural infection as stated in the Methods section of the main manuscript and any of the following criteria:
• Pleural fluid that was macroscopically purulent, OR
• Pleural fluid that was positive on culture for bacterial infection, OR
• Pleural fluid that demonstrated bacteria on Gram staining, OR
• Pleural fluid with pH ≤7.2 (measured in a blood gas analyser) or low glucose level (≤3mmol/L or ≤55mg/dL) in a patient with clinical evidence of infection, OR

You may not qualify if:

• Age less than 18 years, OR
• No pleural fluid available for analysis, OR
• Patient previous pneumonectomy on the side of pleural infection, OR
• Expected survival less than three months due to co-morbid disease, as judged by the recruiting physician

Sponsors & Collaborators

• University of Oxford: lead
• University of Dundee: collaborator

Study Sites (1)

CAMS Oxford Institute, Nuffield Department of Medicine

Oxford, United Kingdom

Location

Related Publications (1)

• Corcoran JP, Psallidas I, Gerry S, Piccolo F, Koegelenberg CF, Saba T, Daneshvar C, Fairbairn I, Heinink R, West A, Stanton AE, Holme J, Kastelik JA, Steer H, Downer NJ, Haris M, Baker EH, Everett CF, Pepperell J, Bewick T, Yarmus L, Maldonado F, Khan B, Hart-Thomas A, Hands G, Warwick G, De Fonseka D, Hassan M, Munavvar M, Guhan A, Shahidi M, Pogson Z, Dowson L, Popowicz ND, Saba J, Ward NR, Hallifax RJ, Dobson M, Shaw R, Hedley EL, Sabia A, Robinson B, Collins GS, Davies HE, Yu LM, Miller RF, Maskell NA, Rahman NM. Prospective validation of the RAPID clinical risk prediction score in adult patients with pleural infection: the PILOT study. Eur Respir J. 2020 Nov 26;56(5):2000130. doi: 10.1183/13993003.00130-2020. Print 2020 Nov.

  PMID: 32675200 BACKGROUND

Biospecimen

Retention: SAMPLES WITHOUT DNA

Acellular pleural fluid specimens were analysed

MeSH Terms

Conditions

Inflammation

Condition Hierarchy (Ancestors)

Pathologic Processes; Pathological Conditions, Signs and Symptoms

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: September 10, 2025
• First Posted: September 26, 2025
• Study Start: January 9, 2024
• Primary Completion: August 31, 2025
• Study Completion: October 1, 2025
• Last Updated: September 26, 2025

Record last verified: 2025-09

Data Sharing

• IPD Sharing: Will not share

Locations

GB (1)